Skinject

Executive Summary

Skinject is a development-stage biotech company based in San Diego, founded in 2018, that is developing a novel dissolvable microneedle array patch for the treatment of basal cell carcinoma and squamous cell carcinoma, the two most common forms of non-melanoma skin cancer. The Skinject Patch aims to provide a less invasive, office-based alternative to current surgical treatments, potentially reducing patient discomfort, scarring, and healthcare costs. The company is privately held and has not disclosed funding rounds or valuation, but its focus on a high-prevalence indication (over 5 million cases in the U.S. annually) positions it for significant market opportunity if clinical development succeeds. As a preclinical-stage asset, Skinject faces typical risks including regulatory hurdles, manufacturing scalability, and clinical efficacy. However, the technology's differentiation through painless, self-administered delivery could disrupt the standard of care, and the company's lean structure suggests potential for strategic partnerships or acquisition by larger dermatology-focused pharma. Near-term progress is contingent on advancing toward Investigational New Drug (IND) application and initial clinical trials.

Upcoming Catalysts (preview)

• Q1 2027IND Submission or FDA Clearance50% success
• Q2 2027First Patient Dosed in Phase 1 Trial40% success
• Q4 2026Strategic Partnership or Series A Funding35% success